Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Europe Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Country 2025-2033
Report Format: PDF+Excel | Report ID: SR112024A5508
Buy Now
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Europe Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Country
8.1 Germany
8.1.1 Market Trends
8.1.2 Market Breakup by Drug Class
8.1.3 Market Breakup by End User
8.1.4 Market Forecast
8.2 France
8.2.1 Market Trends
8.2.2 Market Breakup by Drug Class
8.2.3 Market Breakup by End User
8.2.4 Market Forecast
8.3 United Kingdom
8.3.1 Market Trends
8.3.2 Market Breakup by Drug Class
8.3.3 Market Breakup by End User
8.3.4 Market Forecast
8.4 Italy
8.4.1 Market Trends
8.4.2 Market Breakup by Drug Class
8.4.3 Market Breakup by End User
8.4.4 Market Forecast
8.5 Spain
8.5.1 Market Trends
8.5.2 Market Breakup by Drug Class
8.5.3 Market Breakup by End User
8.5.4 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Breakup by Drug Class
8.6.3 Market Breakup by End User
8.6.4 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
List of Figures
Figure 1: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2019-2024
Figure 3: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
Figure 4: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
Figure 5: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Country (in %), 2024
Figure 6: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 7: Europe: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2019 & 2024
Figure 8: Europe: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 9: Europe: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2019 & 2024
Figure 10: Europe: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 11: Europe: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2019 & 2024
Figure 12: Europe: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 13: Europe: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2019 & 2024
Figure 14: Europe: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 15: Europe: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2019 & 2024
Figure 16: Europe: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 17: Europe: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2019 & 2024
Figure 18: Europe: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 19: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2019 & 2024
Figure 20: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
Figure 21: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
Figure 22: Germany: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 23: France: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2019 & 2024
Figure 24: France: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
Figure 25: France: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
Figure 26: France: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 27: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2019 & 2024
Figure 28: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
Figure 29: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
Figure 30: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 31: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2019 & 2024
Figure 32: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
Figure 33: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
Figure 34: Italy: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 35: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2019 & 2024
Figure 36: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
Figure 37: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
Figure 38: Spain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 39: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2019 & 2024
Figure 40: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2025-2033
Figure 41: Europe: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 42: Europe: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 43: Europe: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2024 and 2033
Table 2: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2025-2033
Table 3: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2025-2033
Table 4: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Country (in Million US$), 2025-2033
Table 5: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Structure
Table 6: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players
Purchase Options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-714-6104
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More
IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.
Read More
I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested
Read More
Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.
Read More
The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.
Read More
I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you
Read More
The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.
Read More
One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.
Read More
We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.
Read More
The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.
Read More
The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.
Read More
The report is excellent and has good amount of data and our team is extremely happy with the information provided.
Read More
Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.
Read More